In the phase II ProCAID clinical trial, the combination of Capivasertib and docetaxel improved survival in metastatic castration-resistant PCa (mCRPC) patients, regardless of PTEN status[19]. This evidence concerns the gene PTEN and posterior cortical atrophy.